ANI Pharmaceuticals Inc [ANIP] stock is trading at $84.83, down -0.54%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ANIP shares have gain 11.21% over the last week, with a monthly amount glided 4.60%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ANI Pharmaceuticals Inc [NASDAQ: ANIP] stock has seen the most recent analyst activity on July 10, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $84. Previously, Jefferies started tracking the stock with Buy rating on March 14, 2025, and set its price target to $80. On March 12, 2025, JP Morgan initiated with an Overweight rating and assigned a price target of $85 on the stock. Leerink Partners started tracking the stock assigning an Outperform rating and suggested a price target of $80 on December 11, 2024. Piper Sandler initiated its recommendation with an Overweight and recommended $68 as its price target on October 11, 2024. CapitalOne started tracking with an Overweight rating for this stock on March 15, 2024, and assigned it a price target of $80. In a note dated August 22, 2023, H.C. Wainwright reiterated a Buy rating on this stock and boosted its target price from $60 to $73.
ANI Pharmaceuticals Inc [ANIP] stock has fluctuated between $54.10 and $99.50 over the past year. Currently, Wall Street analysts expect the stock to reach $107.25 within the next 12 months. ANI Pharmaceuticals Inc [NASDAQ: ANIP] shares were valued at $84.83 at the most recent close of the market. An investor can expect a potential return of 26.43% based on the average ANIP price forecast.
Analyzing the ANIP fundamentals
ANI Pharmaceuticals Inc [NASDAQ:ANIP] reported sales of 826.88M for the trailing twelve months, which represents a growth of 53.58%. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at 0.07%, Pretax Profit Margin comes in at 0.06%, and Net Profit Margin reading is 0.05%. To continue investigating profitability, this company’s Return on Assets is posted at 0.03, Equity is 0.08 and Total Capital is 0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.64.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, ANI Pharmaceuticals Inc’s Current Ratio is 2.58. As well, the Quick Ratio is 2.04, while the Cash Ratio is 0.97. Considering the valuation of this stock, the price to sales ratio is 2.31, the price to book ratio is 3.77 and price to earnings (TTM) ratio is 52.02.
Transactions by insiders
Recent insider trading involved Cook Meredith, SR. VP, GENERAL COUNSEL & SEC., that happened on Jan 13 ’26 when 500.0 shares were sold. SVP, CHIEF HR OFFICER, Davis Krista completed a deal on Dec 18 ’25 to sell 1622.0 shares. Meanwhile, SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold 400.0 shares on Dec 12 ’25.
